Breakthrough Therapy designation is an FDA process “designed to expedite the development and review of drugs” for serious conditions (FDA). A drug qualifies when preliminary clinical evidence suggests it may substantially improve on available therapy, and the designation brings intensive FDA guidance, beginning as early as phase 1 (FDA).
Psychedelic drugs have received it. A 2021 review notes that psilocybin received it for treatment-resistant depression and MDMA for PTSD (Bird et al., 2021). Compass Pathways says its psilocybin product, COMP360, was designated in 2018 (Form 10-Q, 5 August 2026).
The term is often misread. It says the early evidence looked promising enough for closer FDA attention; it doesn’t say the drug works or is safe. MDMA-assisted therapy had the designation and was still not approved in 2024 (Lykos Therapeutics, 2024). It is a US status and has no direct effect on Health Canada decisions.
Sources
- FDA: Breakthrough Therapy
- Bird, Modlin and Rucker, International Review of Psychiatry, 2021
- COMPASS Pathways Form 10-Q, 5 August 2026
Last checked .